Lexeo Therapeutics, Inc. (LXEO) Stock Price & Analysis

Lexeo Therapeutics, Inc. (LXEO) is trading at USD 3.03, up 6.13% today, as of November 18, 2026 at 20:53 UTC (US market open; quotes may be delayed), according to Nexqual market data.

LXEO last closed at USD 2.86; today's session has ranged USD 2.76–3.09 on volume of 1,517,470 shares. Market capitalization is $250.85M, with a 52-week range of USD 2.55–10.99 (NGM). Source: Nexqual, retrieved November 18, 2026 at 20:53 UTC.

Also available as compact Markdown for AI agents: nexqual.com/LXEO.md

Key facts (LXEO)

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (LXEO)

USDFY2022FY2023FY2024FY2025TTM
Revenue$654K————
Operating income-$60.5M-$68.5M-$106M-$109M-$114M
Net income-$59.3M-$66.4M-$98.3M-$100.0M-$105M
EPS (diluted)-$36.36-$12.40-$3.09-$1.86—
Free cash flow-$55.2M-$59.6M-$81.6M-$99.0M-$87.7M
Operating margin-9252.1%————
Net margin-9063.8%————
Cash + short-term investments$77.3M$121M$129M$182M—

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Sep 30, 2026) (LXEO)

P/B 1.2x · FCF yield -34.97% · Earnings yield -41.97%

Insider sales (SEC Form 4, open-market, last ~7 months) (LXEO)

0 of 9 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

Trade dateInsiderRoleSharesValue% of holdings sold10b5-1 planInsider type
2026-08-18Tamayo Louis EdwardChief Financial Officer4,117$20K4.2%NoToo little history (no open-market trades in 2023–2025)
2026-08-18Townsend Richard NolanChief Executive Officer3,345$17K0.9%NoToo little history (no open-market trades in 2023)
2026-08-18Otero Jose ManuelChief Operating Officer1,304$6K0.9%NoToo little history (no open-market trades in 2023 or 2024)
2026-07-01Tamayo Louis EdwardChief Financial Officer4,641$21K4.6%NoToo little history (no open-market trades in 2023–2025)
2026-07-01Otero Jose ManuelChief Operating Officer4,666$21K3.3%NoToo little history (no open-market trades in 2023 or 2024)
2026-07-01Bhalla Narinder PalChief Medical Officer22,306$99K21.3%NoToo little history (no open-market trades in 2023–2025)
2026-07-01Townsend Richard NolanChief Executive Officer25,947$116K6.4%NoToo little history (no open-market trades in 2023)
2026-05-18Otero Jose ManuelChief Operating Officer1,302$7K1%NoToo little history (no open-market trades in 2023 or 2024)
2026-05-18Townsend Richard NolanChief Executive Officer3,342$17K1%NoToo little history (no open-market trades in 2023)

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (LXEO)

Consensus Buy (mean 1.78 on a 1–5 scale), 9 analysts; mean target USD 25.11 (low 9, high 42).

Rating changes, last 120 days:

DateFirmActionRatingPrice target
2026-11-12Cantor FitzgeraldReiteratedOverweight$23
2026-09-23Leerink PartnersMaintainedOutperform$15

Total return (dividends reinvested) (LXEO)

1Y (from 2025-11-18)5Y (from 2023-10-30)
Total return-67.0%-69.8%
S&P 500 (SPY)+11.9%+66.7%
Per year-67.0%-32.5%
Volatility (annualized)73.9%102.5%
Max drawdown-75.3% (Dec 2025→Oct 2026)-88.8% (Jul 2024→Apr 2025)

Dividends (LXEO)

LXEO paid no cash dividend in the last five years.

Short interest (LXEO)

17,037,063 shares sold short, 23.98% of the float, as of Oct 30, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 30, 2026): 19,246,976 shares (-11.5%). Days to cover: 10.5 (short shares ÷ average daily volume).

LXEO earnings history and stock reaction

Results filedQuarterEPSConsensusSurpriseStock reaction
Nov 16, 2026Quarter ended Sep 30, 2026−$0.43−$0.32Miss −34.4%-0.5%
Aug 12, 2026Quarter ended Jun 30, 2026−$0.30−$0.28Miss −7.1%+3.8%
May 11, 2026Quarter ended Mar 31, 2026−$0.25−$0.30Beat +16.7%-2.2%
Mar 30, 2026Quarter ended Dec 31, 2025−$0.27−$0.30Beat +10.0%+5.1%
Nov 5, 2025————+0.8%
Oct 17, 2025————+5.1%
Aug 14, 2025————+0.0%
May 12, 2025————+5.2%

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

LXEO recent SEC filings (last 120 days)

FiledFormWhat it says
Nov 16, 2026Schedule 13G/AOrbiMed Advisors LLC, OrbiMed Capital LLC: 3.9% of shares, passive 5%+ holder (amended)
Nov 16, 2026Schedule 13G/AVestal Point Capital, LP, Ryan Wilder: 6.3% of shares, passive 5%+ holder (amended)
Nov 16, 2026Schedule 13G/AParadigm BioCapital Advisors LP, Paradigm BioCapital Advisors GP LLC: 0.0% of shares, passive 5%+ holder (amended)
Nov 16, 2026Schedule 13G/AJANUS HENDERSON GROUP Ltd.: 7.2% of shares, passive 5%+ holder (amended)
Nov 16, 202610-QQuarterly report · period ended Sep 30, 2026
Nov 16, 20268-KQuarterly results; Regulation FD disclosure; Other material event
“In the press release described in Item 2.02 above, the Company announced positive interim Phase I/II clinical data and regulatory updates for LX2020 for the treatment of PKP2-associated arrhythmogenic cardiomyopathy (" PKP2-ACM "). As part of the press release, the Company announced that it would be hosting a conference call and webcast at 8:00 a.m. ET on November 16, 2026 to discuss the interim Phase I/II clinical data of LX2020 for the treatment of PKP2-ACM. Also on November 16, 2026, the Company posted on its…”
Nov 16, 2026Schedule 13G/ABALYASNY ASSET MANAGEMENT L.P., BAM GP LLC: 10.0% of shares, passive 5%+ holder (amended)
Nov 13, 2026Schedule 13G/AAffinity Asset Advisors, LLC, Michael Cho: 9.8% of shares, passive 5%+ holder (amended)
Nov 10, 2026Schedule 13GSTATE STREET CORPORATION: 4.4% of shares, passive 5%+ holder
Oct 13, 2026Schedule 13Gpassive 5%+ holder
Sep 29, 20268-KCompleted an acquisition or sale of assets; Unregistered sale of shares
Sep 22, 20268-KEntered a material agreement; Other material event
Aug 14, 2026Schedule 13Gpassive 5%+ holder
Aug 14, 2026Schedule 13G/Apassive 5%+ holder (amended)

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

LXEO suppliers, customers and competitors (named in its 10-K)

RelationshipCompanySentence in the filing
PartnerSolid Biosciences Inc. (SLDB)“With respect to LX2006, we are aware of clinical stage gene therapy programs in development at Solid Biosciences Inc. and those being developed in collaborations between Voyager Therapeutics, Inc. and Neurocrine Biosciences, Inc. Among other treatment modalities for FA, we are aware that Larimar Therapeutics, Inc. is developing a clinical stage product candidate, CTI-1601, and that PTC Therapeutics, Inc. is evalua…”
PartnerVoyager Therapeutics, Inc. (VYGR)“With respect to LX2006, we are aware of clinical stage gene therapy programs in development at Solid Biosciences Inc. and those being developed in collaborations between Voyager Therapeutics, Inc. and Neurocrine Biosciences, Inc. Among other treatment modalities for FA, we are aware that Larimar Therapeutics, Inc. is developing a clinical stage product candidate, CTI-1601, and that PTC Therapeutics, Inc. is evalua…”
PartnerNEUROCRINE BIOSCIENCES INC (NBIX)“With respect to LX2006, we are aware of clinical stage gene therapy programs in development at Solid Biosciences Inc. and those being developed in collaborations between Voyager Therapeutics, Inc. and Neurocrine Biosciences, Inc. Among other treatment modalities for FA, we are aware that Larimar Therapeutics, Inc. is developing a clinical stage product candidate, CTI-1601, and that PTC Therapeutics, Inc. is evalua…”
PartnerLarimar Therapeutics, Inc. (LRMR)“With respect to LX2006, we are aware of clinical stage gene therapy programs in development at Solid Biosciences Inc. and those being developed in collaborations between Voyager Therapeutics, Inc. and Neurocrine Biosciences, Inc. Among other treatment modalities for FA, we are aware that Larimar Therapeutics, Inc. is developing a clinical stage product candidate, CTI-1601, and that PTC Therapeutics, Inc. is evalua…”
PartnerPTC THERAPEUTICS, INC. (PTCT)“With respect to LX2006, we are aware of clinical stage gene therapy programs in development at Solid Biosciences Inc. and those being developed in collaborations between Voyager Therapeutics, Inc. and Neurocrine Biosciences, Inc. Among other treatment modalities for FA, we are aware that Larimar Therapeutics, Inc. is developing a clinical stage product candidate, CTI-1601, and that PTC Therapeutics, Inc. is evalua…”
PartnerCornell University and Adverum Biotechnologies“In January 2021, we entered into a license agreement with Adverum, which we amended in February 2022 pursuant to the First Amendment to the Adverum Agreement, such agreement as amended, the Amended Adverum Agreement.”
PartnerStelios Therapeutics“The net decrease of $10.3 million in total research and development expenses for the year ended December 31, 2025 compared to the year ended December 31, 2024 was primarily due to decreases in (i) milestone expenses of $6.1 million, consisting primarily of a $6.0 million development milestone for our LX2020 program that was achieved during the third quarter of 2024 and subsequently paid to the selling shareholders…”
PartnerJohnson & Johnson (JNJ)“Abiomed, Inc. (Johnson & Johnson subsidiary)—In December 2025, the Company entered into a Collaboration Agreement with Abiomed, Inc. ("Abiomed" and the "Abiomed Agreement"), to investigate localized cardiac delivery of gene therapy.”

Quoted from the company's 10-K filed Mar 30, 2026.

LXEO company outlook (results filed Nov 16, 2026)

Quoted word-for-word from the SEC 8-K results press release.

LXEO analyst estimates and revisions

PeriodEPS estimate90 days agoChangeRevenue estimateAnalysts
Current quarter (ends Dec 2026)$-0.35$-0.33−$0.02$07
Next quarter (ends Mar 2027)$-0.36$-0.34−$0.02$04
Current fiscal year (ends Dec 2026)$-1.34$-1.20−$0.14$06
Next fiscal year (ends Dec 2027)$-1.44$-1.38−$0.06$08

LXEO options: expected move

ExpirationDaysATM implied volatilityExpected move
Nov 20, 20262314.0%±99.5%
Dec 18, 20263068.8%±19.4%
Feb 19, 20279374.3%±123.8%
May 21, 2027184388.0%±37.3%

30-day implied volatility 101.5% vs 95.3% realized over the last 30 trading days. Put/call ratio (volume) 0.59. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of November 18, 2026 at 20:53 UTC)

PriceUSD 3.03
Change▲ 6.13% (up)
Previous CloseUSD 2.86
OpenUSD 2.81
Day RangeUSD 2.76 – 3.09
52-Week RangeUSD 2.55 – 10.99
Volume1,517,470 shares
Market Cap$250.85M
ExchangeNGM

Technical Analysis (LXEO)

Nexqual's technical model rates LXEO "SELL" based on 1 bullish and 4 bearish signals across 129 daily candles, as of November 18, 2026 at 20:53 UTC.

Overall SignalSELL
RSI (14)47.59 (neutral)
vs SMA50Below (USD 3.28)
MACD-0.07 (negative)

Analyst Ratings (LXEO)

Wall Street analysts rate LXEO "Buy" based on 9 analysts, with a mean price target of USD 25.11 (range USD 9–42), per Nexqual as of November 18, 2026 at 20:53 UTC.

Consensus RatingBuy
Analyst Count9
Mean TargetUSD 25.11
High TargetUSD 42
Low TargetUSD 9
Buy / Hold / Sell9 / 0 / 0

Earnings (LXEO)

Next Earnings Date2026-11-16
EPS EstimateUSD -0.35
Revenue Estimate$0

Recent Earnings History

QuarterActual vs Estimate
2026-09-30USD -0.43 vs est -0.32 ▼ miss
2026-06-30USD -0.3 vs est -0.28 ▼ miss
2026-03-31USD -0.25 vs est -0.3 ▲ beat
2025-12-31USD -0.27 vs est -0.3 ▲ beat

Source: Nexqual, November 18, 2026 at 20:53 UTC.

Financials & Fundamentals (LXEO)

Gross Margin+0.00%
Operating Margin+0.00%
Profit Margin+0.00%
ROE-62.39%
Debt / Equity0.03
Current Ratio8.69
Total Cash$194.78M
Total Debt$6.25M

Source: Nexqual, November 18, 2026 at 20:53 UTC.

Financial Health Score (LXEO)

Nexqual rates Lexeo Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of November 18, 2026 at 20:53 UTC.

GrowthMixed — No data
ProfitabilityWeak — Pre-revenue or very early stage
Balance SheetStrong — $195M cash vs $6M debt, net cash position
Cash FlowWeak — Operating cash flow -$99M (FY ended Dec 2025, 10-K)
EfficiencyCritical — ROE -49%, ROA -43.2% (last 4 quarters, SEC)

Ownership (LXEO)

Insider Ownership+0.63%
Institutional Ownership+117.44%
Shares Outstanding82.79M
Float50.23M
Short % of Float+23.98%

Source: Nexqual, November 18, 2026 at 20:53 UTC.

Leadership (LXEO)

Lexeo Therapeutics, Inc. is led by R. Nolan Townsend, CEO & Director, per Nexqual as of November 18, 2026 at 20:53 UTC.

CEO & DirectorR. Nolan Townsend
CFO & Principal Accounting OfficerLouis Tamayo
Co-Founder, Chief Scientific Advisor & Member of Scientific Advisory BoardRonald G. Crystal
Chief Operating OfficerJose Manuel Otero
Senior Vice President of Regulatory AffairsKeith Wonnacott

Major Backers & Investors (LXEO)

Notable institutional backers of Lexeo Therapeutics, Inc. include Affinity Asset Advisors, Llc, Montanova Capital LLC, RA Capital Management, L.P., according to Nexqual as of November 18, 2026 at 20:53 UTC.

Active Investors

InvestorStake
Affinity Asset Advisors, Llc8.75%
Montanova Capital LLC7.71%
RA Capital Management, L.P.6.04%
Frazier Life Sciences Management, L.P. 5.83%
JPMorgan5.54%
Vestal Point Capital, LP5.22%
Citadel5.12%
Balyasny Asset Management LP4.82%

Index Funds (Passive)

FundStake
BlackRock7.22%

Source: Nexqual, November 18, 2026 at 20:53 UTC.

From Lexeo Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-30)

Key Strengths & Strategy (as disclosed to the SEC)

Partnerships

Legal & Regulatory Risks (Item 1A, quoted)

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

SymbolNamePriceChange
KODKodiak Sciences IncUSD 97.7▲ 0.93%
BLTEBelite Bio, IncUSD 156.45▼ 0.81%
ORKAOruka Therapeutics, Inc.USD 95.68▼ 0.67%
IBRXImmunityBio, Inc.USD 6.71▲ 7.11%
IMVTImmunovant, Inc.USD 33.24▲ 0.09%
CGONCG Oncology, Inc.USD 79.85▲ 1.15%

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: November 18, 2026 at 20:53 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt